AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
AMZN   3,057.04 (+5.77%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
AMZN   3,057.04 (+5.77%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
AMZN   3,057.04 (+5.77%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
AMZN   3,057.04 (+5.77%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
Log in

NASDAQ:IGMSIGM Biosciences Stock Price, Forecast & News

$70.82
-1.57 (-2.17 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$70.59
Now: $70.82
$78.32
50-Day Range
$52.73
MA: $63.33
$74.87
52-Week Range
$16.10
Now: $70.82
$80.55
Volume88,870 shs
Average Volume132,557 shs
Market Capitalization$2.17 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IGMS
CUSIPN/A
CIKN/A
Phone650-965-7873

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.88 per share

Profitability

Miscellaneous

Employees40
Market Cap$2.17 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive IGMS News and Ratings via Email

Sign-up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.

IGM Biosciences (NASDAQ:IGMS) Frequently Asked Questions

How has IGM Biosciences' stock been impacted by COVID-19 (Coronavirus)?

IGM Biosciences' stock was trading at $52.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IGMS stock has increased by 35.4% and is now trading at $70.82. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IGM Biosciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IGM Biosciences.

When is IGM Biosciences' next earnings date?

IGM Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for IGM Biosciences.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences (NASDAQ:IGMS) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.58) EPS for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.03. View IGM Biosciences' earnings history.

What price target have analysts set for IGMS?

9 Wall Street analysts have issued 12 month price targets for IGM Biosciences' shares. Their forecasts range from $25.00 to $95.00. On average, they anticipate IGM Biosciences' share price to reach $65.43 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View analysts' price targets for IGM Biosciences.

Has IGM Biosciences been receiving favorable news coverage?

Media headlines about IGMS stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IGM Biosciences earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about IGM Biosciences.

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 727,400 shares, an increase of 9.3% from the May 31st total of 665,300 shares. Based on an average daily volume of 91,600 shares, the short-interest ratio is currently 7.9 days. Approximately 5.6% of the company's stock are short sold. View IGM Biosciences' Current Options Chain.

Who are some of IGM Biosciences' key competitors?

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include AbbVie (ABBV), Pfizer (PFE), Atreca (BCEL), Crispr Therapeutics (CRSP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Axsome Therapeutics (AXSM), Carnival (CCL), Fate Therapeutics (FATE) and Heron Therapeutics (HRTX).

Who are IGM Biosciences' key executives?

IGM Biosciences' management team includes the following people:
  • Mr. Fred M. Schwarzer, CEO, Pres & Director (Age 66)
  • Mr. Misbah Tahir, Chief Financial Officer (Age 44)
  • Dr. Bruce A. Keyt, Chief Scientific Officer (Age 66)
  • Ms. Suzette Tauber, VP of HR (Age 56)
  • Mr. Daniel Chen, Chief Medical Officer (Age 50)

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

How do I buy shares of IGM Biosciences?

Shares of IGMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $70.82.

How big of a company is IGM Biosciences?

IGM Biosciences has a market capitalization of $2.17 billion. The company earns $-43,130,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. IGM Biosciences employs 40 workers across the globe.

What is IGM Biosciences' official website?

The official website for IGM Biosciences is igmbio.com.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-965-7873.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.